Sanctuary Advisors LLC Buys 1,731 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Sanctuary Advisors LLC raised its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 10.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,976 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,731 shares during the period. Sanctuary Advisors LLC owned approximately 0.06% of Collegium Pharmaceutical worth $695,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Louisiana State Employees Retirement System lifted its holdings in shares of Collegium Pharmaceutical by 1.9% during the 2nd quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company’s stock worth $531,000 after acquiring an additional 300 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Collegium Pharmaceutical by 10.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,745 shares of the specialty pharmaceutical company’s stock worth $314,000 after purchasing an additional 959 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Collegium Pharmaceutical by 8.2% during the second quarter. Principal Financial Group Inc. now owns 1,680,860 shares of the specialty pharmaceutical company’s stock worth $54,124,000 after purchasing an additional 128,003 shares during the last quarter. nVerses Capital LLC boosted its holdings in shares of Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 1,600 shares in the last quarter. Finally, Ritholtz Wealth Management increased its stake in shares of Collegium Pharmaceutical by 43.1% in the 2nd quarter. Ritholtz Wealth Management now owns 38,856 shares of the specialty pharmaceutical company’s stock valued at $1,251,000 after purchasing an additional 11,699 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on COLL. Piper Sandler restated a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. HC Wainwright raised their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. Finally, StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $42.60.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $29.06 on Wednesday. The stock has a 50-day moving average price of $32.30 and a two-hundred day moving average price of $34.30. Collegium Pharmaceutical, Inc. has a 12 month low of $28.75 and a 12 month high of $42.29. The company has a market capitalization of $937.19 million, a PE ratio of 12.53 and a beta of 0.80. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.